Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
暂无分享,去创建一个
N. Brown | Chang Yu | H. Nian | M. Pretorius | F. Billings | J. Devin
[1] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[2] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[3] S. Rajagopalan,et al. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. , 2013, Atherosclerosis.
[4] Harumi Uto-Kondo,et al. Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients , 2013, Journal of the American Heart Association.
[5] R. Kubant,et al. Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats , 2012, Journal of cardiovascular pharmacology.
[6] Limei Liu,et al. Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism , 2012, Hypertension.
[7] L H Wang,et al. Serum Levels of Calcitonin Gene-Related Peptide and Substance P are Decreased in Patients with Diabetes Mellitus and Coronary Artery Disease , 2012, The Journal of international medical research.
[8] J. Brazin,et al. Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system. , 2011, Current pharmaceutical design.
[9] M. Netea,et al. Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes , 2011, Diabetes Care.
[10] A. Avogaro,et al. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. , 2011, Vascular pharmacology.
[11] S. Rajagopalan,et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. , 2011, Vascular pharmacology.
[12] S. Ito,et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. , 2011, The Tohoku journal of experimental medicine.
[13] N. Brown,et al. Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans , 2010, Hypertension.
[14] J. Fu,et al. Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus. , 2010, Experimental and clinical endocrinology & diabetes.
[15] F. Sweep,et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. , 2009, The Journal of clinical endocrinology and metabolism.
[16] E. Jackson,et al. EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSURE , 2008, Clinical and experimental pharmacology & physiology.
[17] A. Diedrich,et al. Endogenous substance P modulates human cardiovascular regulation at rest and during orthostatic load. , 2007, Journal of applied physiology.
[18] N. Thornberry,et al. Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin , 2007, Clinical pharmacology and therapeutics.
[19] D. Webb,et al. Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[20] D. Vaughan,et al. Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[21] N. Tublitz,et al. Neurokinin‐1 receptor desensitization to consecutive microdialysis infusions of substance P in human skin , 2005, The Journal of physiology.
[22] M. Yamakawa,et al. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system , 2005, Peptides.
[23] C. Saper,et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. , 2002, The Journal of clinical investigation.
[24] W. Simmons,et al. Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema , 2002, Hypertension.
[25] D. Webb,et al. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. , 2001, Journal of the American College of Cardiology.
[26] J. Morrow,et al. Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. , 2001, Analytical biochemistry.
[27] J. C. Hancock,et al. Enhanced ganglionic responses to substance P in spontaneously hypertensive rats☆ , 2000, Peptides.
[28] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[29] D. Webb,et al. Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. , 1999, British journal of clinical pharmacology.
[30] D. Vaughan,et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. , 1999, Hypertension.
[31] D. Webb,et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. , 1999, Circulation.
[32] B. Livett,et al. Substance P and epibatidine-evoked catecholamine release from fractionated chromaffin cells. , 1997, European journal of pharmacology.
[33] D. Webb,et al. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. , 1997, British journal of clinical pharmacology.
[34] J. C. Hancock,et al. Pressor and tachycardic responses to intravenous substance P in anesthetized rats , 1995, Peptides.
[35] D. Macdonald,et al. Neuropeptides induce rapid expression of endothelial cell adhesion molecules and elicit granulocytic infiltration in human skin. , 1993, Journal of immunology.
[36] J. Pesquero,et al. Bradykinin metabolism pathway in the rat pulmonary circulation , 1992, Journal of hypertension.
[37] Lianguo Wang,et al. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. , 1992, The Journal of pharmacology and experimental therapeutics.
[38] T. Lotti,et al. SUBSTANCE P PROVOKES CUTANEOUS ERYTHEMA AND EDEMA THROUGH A HISTAMINE‐INDEPENDENT PATHWAY , 1992, International journal of dermatology.
[39] S. Mizutani,et al. Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme , 1991, Peptides.
[40] Y. Shimohigashi,et al. Pharmacological Properties of the Tachykinin Receptor Subtype in the Endothelial Cell and Vasodilation , 1991, Annals of the New York Academy of Sciences.
[41] D. Webb,et al. The effect of local converting enzyme inhibition on the dilator response to substance P in the human forearm. , 1990, British journal of clinical pharmacology.
[42] I. Gibbins,et al. Noradrenergic and peptidergic innervation of the extrinsic vessels and microcirculation of the rat cremaster muscle. , 1989, Microvascular research.
[43] J. McEwan,et al. Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms. , 1988, Circulation.
[44] J. Polak,et al. Capsaicin induces a depletion of calcitonin gene-related peptide (CGRP)-immunoreactive nerves in the cardiovascular system of the guinea pig and rat. , 1986, Journal of the autonomic nervous system.
[45] H. Yokosawa,et al. Hydrolysis of substance P and its analogs by angiotensin-converting enzyme from rat lung. Characterization of endopeptidase activity of the enzyme. , 1985, Journal of biochemistry.
[46] M. Gilbert,et al. Tissue plasminogen activator release in vivo in response to vasoactive agents. , 1985, Blood.
[47] C. Charlton,et al. Cardiovascular effects of spinal cord substance P: studies with a stable receptor agonist. , 1985, The Journal of pharmacology and experimental therapeutics.
[48] J. Seegmiller,et al. Cystinosis. Combined clinical staff conference at the National Institutes of Health. , 1968, Annals of internal medicine.
[49] J. Ross,et al. Congestive Heart Failure: Biochemical and Physiological Considerations: Combined Clinical Staff Conference at the National Institutes of Health , 1966 .
[50] E. Braunwald,et al. F. SYMPATHETIC ACTIVITY AND NEUROTRANSMITTER DEPLETION IN CONGESTIVE HEART FAILURE , 1966 .
[51] W. Zeng,et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. , 2006, Clinical therapeutics.
[52] K. Karita,et al. Axon reflex vasodilatation in human skin measured by a laser Doppler technique. , 1991, The Japanese Journal of Physiology.
[53] M. Costa,et al. Neuropeptides contained in peripheral cardiovascular nerves. , 1984, Clinical and experimental hypertension. Part A, Theory and practice.
[54] E. Braunwald,et al. Sympathetic activity and neurotransmitter depletion in congestive heart failure. , 1966, Pharmacological reviews.